New Clinical Trials
LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch

October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] READ MORE

FDA Expedites Existing Drug Gazyva for Lupus Nephritis

September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus.  The FDA’s designation aims to  speed up  the development and review of drugs intended to treat a serious condition […] READ MORE

VALUE Study Results Reported at EULAR

MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] READ MORE

Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

New York, NY– March 1.  The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  The national study will be conducted in 20 research centers throughout the country, many […] READ MORE

Neovacs Announces the Results of its Phase IIb Study for Ifnalpha Kinoid in the Treatment of Lupus Which Allows to Proceed With the Clinical Development into Phase III

July 3, 2018 Neovacs announced the results of its Phase IIb clinical trial of the investigational agent IFNalpha Kinoid in patients with moderate to severe lupus (SLE). The results show that IFNalpha Kinoid very significantly reduced the levels of type I interferon genes in the blood and tissue cells of people with lupus. High levels […] READ MORE

Learn and connect with our community!